STOCK TITAN

The Precision Peptide Company Announces Grants of RSUs and Stock Options

The Precision Peptide Company (PNGAF) authorized on July 31, 2026 the grant of restricted share units and incentive stock options under its omnibus share incentive plan.

(Very Positive)
Tags

The Precision Peptide Company (PNGAF) authorized on July 31, 2026 the grant of restricted share units and incentive stock options under its omnibus share incentive plan.

The company granted 150,000 RSUs and 200,000 stock options to a consultant. Each option allows the purchase of one common share at an exercise price of $0.50 per share for a term of 10 years from the grant date. All RSUs and options are governed by the terms of the plan and applicable securities laws.

Loading...
Loading translation...

Positive

  • 150,000 RSUs granted, enhancing equity-based compensation for a consultant
  • 200,000 options with a 10-year term support long-term incentive alignment

Negative

  • Equity awards of 350,000 potential shares may contribute to future shareholder dilution
Argus Sep 8 session
-0.34% close to close Open Argus
Details

News Market Reaction – PNGAF

In the Sep 8 session, PNGAF declined 0.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Vancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") announces that on July 31, 2026, it has authorized the grant of restricted share units (the "RSUs") and incentive stock options (the "Options") pursuant to the Company's omnibus share incentive plan (the "Plan").

The Company has granted 150,000 RSUs and 200,000 Options to a certain consultant of the Company. Each Option entitles the holder to acquire one common share of the Company ("Share") at an exercise price of $0.50 per Share for a period of ten (10) years from the date of grant. All RSUs and Options are subject to the terms of the Plan and applicable securities laws.

On Behalf of the Board of Directors

"Pratap Sandhu"
Pratap Sandhu
CEO, Corporate Secretary and Director
+1 (604) 765-8069

Cautionary Note Regarding Forward-Looking Information

This news release may contain certain "forward-looking information" under applicable Canadian securities laws. When or if used in this news release, the words "anticipate," "believe," "estimate," "expect", "intend", "target", "plan," "forecast," "may," "schedule," and similar words or expressions identify forward-looking information. Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. The forward-looking information contained in this news release is made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313140

FAQ

What equity awards did The Precision Peptide Company (PNGAF) grant on July 31, 2026?

The Precision Peptide Company granted 150,000 restricted share units (RSUs) and 200,000 incentive stock options to a consultant on July 31, 2026, under its omnibus share incentive plan.

What is the exercise price and term of the new PNGAF stock options?

Each newly granted option allows the holder to acquire one common share at an exercise price of $0.50 per share, with a term of ten years from the date of grant, subject to the plan and securities laws.

Who received the RSUs and stock options from The Precision Peptide Company (PNGAF)?

The 150,000 RSUs and 200,000 stock options were granted to a consultant of The Precision Peptide Company, under its omnibus share incentive plan.

Are the new PNGAF RSUs and options subject to any specific conditions?

Yes. The company states that all granted RSUs and options are subject to the terms of its omnibus share incentive plan and to applicable securities laws.

Keep reading